Saturday 17 October 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.2%, free cash flow grew 5.04% and total debt rose 52.6%, each against the same quarter a year earlier.
10.86
0.89
−7.57%
Follow REPL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (134.29%) | (107.88%) | (90.88%) | (96.24%) |
+8 more TTM periods Free account |
|
| (82.28%) | (71.05%) | (67.19%) | (69.91%) | ||
ROIC |
(1,154.69%) | (8,036.55%) | (1,825.35%) | (2,164.42%) | |
Return on Tangible Assets |
(170.45%) | (134.24%) | (128.98%) | (104.97%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.90) | (3.07) | (3.07) | (2.93) | |
Free Cash Flow |
(280.54) | (284.57) | (283.27) | (269.69) | |
Capital Expenditures |
(1.49) | (4.22) | (5.35) | (7.02) | |
| Other line items | |||||
Cash ROIC |
(68.97%) | (52.67%) | (51.56%) | (41.08%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(29.92) | (36.11) | (40.90) | (40.18) | |
Operating CF/Net income |
0.94 | 0.89 | 0.88 | 0.85 | |
Depreciation/Fixed assets |
0.18 | 0.06 | (0.05) | (0.15) | |
Capex/Depreciation |
(0.71) | (5.37) | 7.04 | 3.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.88) | (3.02) | (3.01) | (2.86) | |
Capex per Share |
(0.02) | (0.05) | (0.06) | (0.08) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates